Caliper Renews Agreement with Agilent for Microfluidic Chips | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Caliper Life Sciences today announced it has renewed its microfluidic chip supply agreement with Agilent Technologies.

Under a new seven-year agreement, Caliper will remain the exclusive supplier of microfluidic chips to Agilent for use on its Bioanalyzer 2100 platforms. Since its launch in 1999, more than 7,000 Bioanalyzer 2100 instruments have been sold, and Caliper has supplied about 5 million chips for use on the platform, Caliper said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.